Biotechnology News and Research

RSS

Vivakor launches new website to promote its remarkable VivaThermic Vial

Vivakor, Inc. today announced the launch of its new website promoting its remarkable VivaThermic Vial at www.vivathermic.com.

14 Dec 2009

Allen & Caron selected as Ohr Pharmaceutical's agency for investor relations

Ohr Pharmaceutical Inc. announced today it has selected Allen & Caron Inc, headquartered in Irvine, CA, with offices also in New York and London, as its agency for investor relations and corporate communications.

14 Dec 2009

ICON expands its European Central Laboratory in Dublin

ICON plc,a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has expanded its European Central Laboratory, located in South County Business Park, Dublin.

14 Dec 2009

BIO commends the House of Representatives for including provisions to ease regulatory burdens

The Biotechnology Industry Organization (BIO) commends the House of Representatives for including provisions intended to ease small business regulatory burdens as part of the Wall Street Reform and Consumer Protection Act of 2009 (H.R. 4173) which passed today.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Genentech announces positive results from Phase II study of T-DM1

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.

14 Dec 2009

Positive interim results of ARRY-380 in Phase 1 trial announced

Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.

13 Dec 2009

Number of new medicines in development to fight diabetes, reports Nabe News in Brooklyn

Nabe News in Brooklyn, New York recently reported that 183 new medicines are in development to fight diabetes. The report details a record number of drugs for this chronic disease currently in human clinical trials and awaiting approval by the U.S. Food and Drug Administration.

13 Dec 2009

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Welichem today announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study.

12 Dec 2009

CONNECT announces the winners of MIP Awards

CONNECT, one of the nation's most successful regional economic development programs for high technology and life science innovators, today announced the winners of the 22nd Annual Most Innovative New Product (MIP) Awards.

11 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Seattle Genetics, Inc. today reported that it has been notified by Genentech, a wholly owned member of the Roche Group, that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab (SGN-40). Dacetuzumab is a monoclonal antibody targeting CD40 that has been investigated in clinical trials for non-Hodgkin lymphoma and multiple myeloma.

11 Dec 2009

Uppsala University Hospital orders CELDA from Likvor for diagnosing NPH

LinkMed’s portfolio company Likvor has received an order for Likvor CELDA™ from Uppsala University Hospital (Akademiska Universitetssjukhuset).

11 Dec 2009

PharmMD raises $8.8 million in capital from The Riverside Company and FCA Ventures IV

PharmMD recently raised $8.8 million in capital from The Riverside Company and FCA Ventures IV, a fund of Clayton Associates.

11 Dec 2009

Study describing solid-state characterization of three forms of finasteride published

Aptuit, Inc. today announced the publication of new research in the December issue of the European Journal of Pharmaceutical Sciences, the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS), which describes the solid-state characterization of three forms of finasteride.

11 Dec 2009

Update on proposed transaction that will lead to the merger of Cytopia into YM BioSciences provided

YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today provided an update on the proposed transaction which would result in the merger of Cytopia Ltd. into YM, details of which were announced on October 5, 2009.

11 Dec 2009

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

11 Dec 2009

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.

11 Dec 2009

Researchers discover new explanation for differences in severity of mental illness in males

Researchers have discovered a new explanation for differences in the severity of mental illness in males. The more excess copies of a certain gene, the more serious the handicap. The genetic defect is situated on the X-chromosome; and it is suspected that it is the amount of copies of the GDI1 gene that is responsible.

11 Dec 2009

HST Global and HMD team up to develop curriculum for FIT protocol

HST Global, Inc. (OTCBB: HSTC) today announced a Partnership with Dr. James W. Forsythe to facilitate the development of a curriculum for the licensing and/or certification to administer Dr. Forsythe’s immune therapy in clinics to be built or acquired by HST Global, Inc.

11 Dec 2009

Biotechnology News and Research

Vivakor launches new website to promote its remarkable VivaThermic Vial

Allen & Caron selected as Ohr Pharmaceutical's agency for investor relations

ICON expands its European Central Laboratory in Dublin

BIO commends the House of Representatives for including provisions to ease regulatory burdens

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech announces positive results from Phase II study of T-DM1

Positive interim results of ARRY-380 in Phase 1 trial announced

Number of new medicines in development to fight diabetes, reports Nabe News in Brooklyn

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

CONNECT announces the winners of MIP Awards

Zevalin clinical data presented at 2009 ASH meeting

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Uppsala University Hospital orders CELDA from Likvor for diagnosing NPH

PharmMD raises $8.8 million in capital from The Riverside Company and FCA Ventures IV

Study describing solid-state characterization of three forms of finasteride published

Update on proposed transaction that will lead to the merger of Cytopia into YM BioSciences provided

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Researchers discover new explanation for differences in severity of mental illness in males

HST Global and HMD team up to develop curriculum for FIT protocol

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News